The GLP-1 Era: Obesity, Kidney, Heart, and Brain
For some time now, an interesting scene has been repeating itself in the clinic. A significant number of patients over 60, slightly overweight, with borderline blood pressure and diabetes, now sit down with the same question: "Doctor, would those GLP-1 injections work for me too?" The molecules we used to call "diabetes medication" now play a role in a much wider range of conditions, from cardiovascular disease and dementia to kidney and liver problems. Marketing a treatment
Jan 317 min read
The Math of Aging: Why Does the Risk of Death Double Every 8 Years?
You look at two people of the same age, 68 and 68 on paper, but one climbs the stairs without a change in breath, while the other is leaning against the wall on the second floor. Their chronological age is the same, but the risk of death, the burden of disease, and the functional decline seem to follow a completely different timeline. The 3Ds of aging – Death, Disease, Decline – are precisely trying to understand these diverging timelines. Gompertz's mathematics: How does the
Jan 316 min read
Epigenetic Clock: Youth in 6 Days, Cancer in 12 Days
When discussing "aging" in the clinic, most patients think it's just wrinkles and fatigue. But what we call the "epigenetic clock," which measures aging in the laboratory, works like software imprinted on the cell's identity. And it's now known how this software can be reversed with a short intervention: partial reprogramming . For the past 30 years, the classic narrative has been: if you want to rejuvenate a cell, you need to make it fundamentally "pluripotent." But the r
Jan 316 min read
.jpeg)
